The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo proteins that fold in a particular way and bind to prespecified target proteins. The sister system, called Alphadesign, works by generating random strings of amino acids, using Alphafold to predict their structure, and then iteratively optimizing the design.

The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo proteins that fold in a particular way and bind to prespecified target proteins. The sister system, called Alphadesign, works by generating random strings of amino acids, using Alphafold to predict their structure, and then iteratively optimizing the design.

Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions.

Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions to analyze the microbiome differences and their effects after transplantation form different intestine areas. The results show how host-microbe mismatches after these interventions could affect gut health.

Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions to analyze the microbiome differences and their effects after transplantation form different intestine areas. The results show how host-microbe mismatches after these interventions could affect gut health.

Researchers at the Massachusetts Institute of Technology and Recursion Pharmaceuticals Inc. have released an open-source AI model that can predict the binding strength of small molecules as well as structures of proteins and biomolecular complexes. The model, which is called Boltz-2 and was released by the research team on the developer platform Github on June 6, addresses a major bottleneck in drug discovery with its improved ability to predict binding strengths.

Researchers at the Massachusetts Institute of Technology and Recursion Pharmaceuticals Inc. have released an open-source AI model that can predict the binding strength of small molecules as well as structures of proteins and biomolecular complexes. The model, which is called Boltz-2 and was released by the research team on the developer platform Github on June 6, addresses a major bottleneck in drug discovery with its improved ability to predict binding strengths.

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune cells may explain the worse prognosis in people with this alteration. The loss of the Y chromosome (LOY) is one of the most frequent somatic mutations in men, particularly with advancing age. Investigating the mechanisms and effects of LOY in peripheral blood mononuclear cells and its association with immune and tumor cells, they “found a relationship between the Y chromosome loss in normal cells inside the tumor and the Y chromosome loss inside the cancer cell,” Dan Theodorescu, senior author of the study, told BioWorld.

A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on Aging published on June 5, 2025, in Science has stated that the impact of taurine supplementation at delaying aging or treating aging-related conditions is context-dependent, and that the circulating levels of taurine are impacted by factors unique to each individual rather than declining with age. To qualify taurine as a true marker of aging, it should change with age across diverse populations over time and ideally supported by longitudinal data.

A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on Aging published on June 5, 2025 in Science has stated that the impact of taurine supplementation at delaying aging or treating aging-related conditions is context-dependent, and that the circulating levels of taurine are impacted by factors unique to each individual rather than declining with age. To qualify taurine as a true marker of aging, it should change with age across diverse populations over time and ideally supported by longitudinal data.